Clinical Trial Update: A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104 [Phase 1]

View source ↗

Summary

Phase I clinical trial evaluating the safety and immunogenicity of DX-104 for meningococcal disease due to Neisseria meningitidis serogroup B; currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease Caused By Neisseria Meningitidis Serogroup

Drugs mentioned

• DX-104

Snippet

Sponsor: Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks) | Conditions: Neisseria Meningitidis Serogroup B | Phase 1 | Status: RECRUITING